Next Article in Journal
Synthesis of Silver Nanoparticles Using Odontosoria chinensis (L.) J. Sm. and Evaluation of their Biological Potentials
Next Article in Special Issue
The Rationale for Potential Pharmacotherapy of COVID-19
Previous Article in Journal
Oleacein and Foam Cell Formation in Human Monocyte-Derived Macrophages: A Potential Strategy against Early and Advanced Atherosclerotic Lesions
Previous Article in Special Issue
Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses
Open AccessOpinion

COVID-19: A Brief Overview of the Discovery Clinical Trial

Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium
Pharmaceuticals 2020, 13(4), 65; https://doi.org/10.3390/ph13040065
Received: 4 April 2020 / Revised: 8 April 2020 / Accepted: 9 April 2020 / Published: 10 April 2020
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
The outbreak of COVID-19 is leading to a tremendous search for curative treatments. The urgency of the situation favors a repurposing of active drugs but not only antivirals. This short communication focuses on four treatments recommended by WHO and included in the first clinical trial of the European Discovery project. View Full-Text
Keywords: chloroquine; COVID-19; hydroxychloroquine; lopinavir/ritonavir; remdesivir; repurposing; SARS-CoV-2 chloroquine; COVID-19; hydroxychloroquine; lopinavir/ritonavir; remdesivir; repurposing; SARS-CoV-2
Show Figures

Figure 1

MDPI and ACS Style

Vanden Eynde, J.J. COVID-19: A Brief Overview of the Discovery Clinical Trial. Pharmaceuticals 2020, 13, 65.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop